Jia Min Ho
About Jia Min Ho
Jia Min Ho is a Research Associate II at Lucence in Singapore, specializing in translational cancer research. With a Bachelor of Science in Biological and Biomedical Sciences from Monash University Malaysia, she has contributed to significant publications in lung cancer diagnosis and has experience in various research roles.
Work at Lucence Health
Jia Min Ho currently serves as a Research Associate II at Lucence Health, a position held since 2021. In this role, she focuses on translational cancer research, specifically developing novel therapeutic strategies for cancer treatment. Her work encompasses a variety of methodologies, including cell-based experiments and clinical trials. Prior to her current position, she worked as a Research Associate I at Lucence for one year, where she contributed to ongoing research initiatives.
Education and Expertise
Jia Min Ho earned her Bachelor of Science (B.Sc.) in Biological and Biomedical Sciences from Monash University Malaysia, completing her studies from 2012 to 2016. She also pursued a Bachelor of Science (HONS) in Cell Death and Immunology at the same institution for one year, from 2015 to 2016. Earlier, she obtained GCE-A levels in Biology, Chemistry, and Mathematics from INTI International University & Colleges. Her educational background supports her specialization in translational cancer research.
Background
Before joining Lucence Health, Jia Min Ho worked at the National Cancer Centre Singapore as a Research Officer from 2017 to 2020. In this role, she gained valuable experience in cancer research. Additionally, she was a Summer Research Student at Monash University Malaysia for one month in 2013, where she began her research career. Her background reflects a consistent focus on cancer-related research and methodologies.
Achievements
Jia Min Ho has co-authored significant publications in the field of cancer research. Notably, she contributed to a publication on liquid biopsy in combination with PET/CT for lung cancer diagnosis, which was presented at the Journal of Clinical Oncology in 2023. Additionally, she co-authored a publication on plasma cell-free RNA (cfRNA) sequencing for lung cancer detection, presented at the 2023 World Conference on Lung Cancer. These contributions highlight her active involvement in advancing cancer diagnostic methodologies.